Sidoti & Co. analyst Mitra Ramgopal upgrades Transcat (NASDAQ:TRNS) from Neutral to Buy and announces $60 price target.
Why Is Dicerna Stock Getting Slammed Today?
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) announced top-line results from PHYOX2 pivotal trial of nedosiran, RNAi therapeutic, for primary hyperoxaluria (PH). The trial…